Estefânia Vargas holds a B.Sc. in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro (UTAD). She is currently in the second year of her Master’s degree in Biomedicine – Specialization in Clinical Genetics within the UTAD and UFP consortium. She is conducting her dissertation project at the Life and Health Sciences Research Institute (ICVS), University of Minho (UM). She is supervised by Professor Patrícia Maciel and Dr. Daniela Monteiro-Fernandes within the Translational Neurogenetics team. The project focuses on exploring novel targeted protein degraders that enhance ataxin-3 degradation, as candidate therapeutics for Machado-Joseph disease.
Estefânia Vargas holds a B.Sc. in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro (UTAD). She is currently in the second year of her Master’s degree in Biomedicine – Specialization in Clinical Genetics within the UTAD and UFP consortium. She is conducting her dissertation project at the Life and Health Sciences Research Institute (ICVS), University of Minho (UM). She is supervised by Professor Patrícia Maciel and Dr. Daniela Monteiro-Fernandes within the Translational Neurogenetics team. The project focuses on exploring novel targeted protein degraders that enhance ataxin-3 degradation, as candidate therapeutics for Machado-Joseph disease.
Departing from previous work in which we developped cellular and animal models of Machado-Joseph disease, a neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein ataxin-3 (ATXN3)…
